[Federal Register Volume 87, Number 34 (Friday, February 18, 2022)]
[Notices]
[Page 9362]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03555]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP)--RFA-PS-22-001, Implementing Pre-Exposure 
Prophylaxis for HIV Prevention in Syringe Service Programs; RFA-PS-22-
002, Implementation Research on Telehealth Strategies To Support 
Retention in Care and Treatment Among Antiretroviral Therapy (ART) 
Patients and Pre-Exposure Prophylaxis (PrEP) Clients and RFA-PS-22-004, 
Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging 
in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who 
Have Sex With Men in a Transformational Era; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the Disease, 
Disability, and Injury Prevention and Control Special Emphasis Panel 
(SEP) RFA-PS-22-001, Implementing Pre-exposure Prophylaxis for HIV 
Prevention in Syringe Service Programs; RFA-PS-22-002, Implementation 
Research on Telehealth Strategies to support Retention in Care and 
Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure 
Prophylaxis (PrEP) Clients; and RFA-PS-22-004, Understanding HIV/STD 
Risk and Enhancing PrEP Implementation Messaging in a Diverse 
Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex 
with Men in a Transformational Era.

    Date: March 30, 2022.
    Time: 10:00 a.m.-5:00 p.m. (EDT).
    Place: Teleconference.
    The meeting was published in the Federal Register on February 4, 
2022, Volume 87, Number 24, page 6562-6563.
    The meeting is being amended to remove RFA-PS-22-002, 
Implementation Research on Telehealth Strategies to Support Retention 
in Care and Treatment among Antiretroviral Therapy (ART) Patients and 
Pre-exposure Prophylaxis (PrEP) Clients and should read as follows:
    RFA-PS-22-001, Implementing Pre-exposure Prophylaxis for HIV 
Prevention in Syringe Service Programs and RFA-PS-22-004, Understanding 
HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse 
Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex 
with Men in a Transformational Era.
    The meeting is closed to the public.
    For Further Information Contact: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, National Center for HIV, Viral Hepatitis, 
STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, 
Atlanta, Georgia 30329, Telephone: (404) 718-8833, Email: 
[email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-03555 Filed 2-17-22; 8:45 am]
BILLING CODE 4163-18-P